These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 11988242

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L, INCOMIN Trial Study Group.
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [Abstract] [Full Text] [Related]

  • 3. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L.
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [Abstract] [Full Text] [Related]

  • 4. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.
    Neurology; 1999 Sep 11; 53(4):679-86. PubMed ID: 10489026
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A, Murray TJ, PROOF Study Investigators.
    Curr Med Res Opin; 2008 Apr 11; 24(4):1049-55. PubMed ID: 18315940
    [Abstract] [Full Text] [Related]

  • 6. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL, Scott LJ.
    CNS Drugs; 2004 Apr 11; 18(8):521-46. PubMed ID: 15182221
    [Abstract] [Full Text] [Related]

  • 7. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.
    Durelli L.
    J Neurol; 2003 Dec 11; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396
    [Abstract] [Full Text] [Related]

  • 8. The importance of maintaining effective therapy in multiple sclerosis.
    Durelli L, Clerico M.
    J Neurol; 2005 Sep 11; 252 Suppl 3():iii38-iii43. PubMed ID: 16170500
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 11; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early treatment and dose optimisation BENEFIT and BEYOND.
    Hartung HP.
    J Neurol; 2005 Sep 11; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L.
    J Neurol Sci; 2004 Jul 15; 222(1-2):13-9. PubMed ID: 15240190
    [Abstract] [Full Text] [Related]

  • 19. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2016 Nov 24; 11(11):CD009333. PubMed ID: 27880972
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.